


Amendments to the Claims:

Claims 1-7 (Cancelled)

Claim 8. (Currently amended): Compound A compound of formula (I')



in which


R'1 is halogen, a CF₃, (C₁-C₄) alkyl or (C₁-C₄) alkoxy group;

R'2 is (C₁-C₆) alkyl, (C₁-C₆) alkoxy; halogen, a CF₃ group, hydroxy, a group selected from (C₃-C₇) cycloalkyl, phenyl, phenoxy, phenylmethyl or phenylethyl, said group being optionally mono- or polysubstituted on the phenyl group by halogen, CF₃, (C₁-C₄) alkyl or (C₁-C₄) alkoxy;

R'3 is hydrogen, (C₁-C₆) alkyl, (C₁-C₆) alkoxy, halogen, a CF₃ group or hydroxy;

~~as well as their salts and solvates and their or a salt or quaternary ammonium salts salt thereof.~~

Claim 9. (Currently amended): Compound A compound according to Claim 8 of formula (I'')




where X⁻ is a pharmaceutically acceptable anion, Alk is (C₁-C₄) alkyl and R'1, R'2 and R'3 are as defined [for the compounds (I')] in Claim 8.

Claim 10. (Currently amended): Compound A compound according to Claim 8 selected from the group consisting of:


1-{2-(3'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(2'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(4'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(4-isobutylphenyl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(4-benzylphenyl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(4-cyclohexylphenyl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(4'-fluorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(4-n-butylphenyl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(biphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(4-t-butylphenyl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(3,4-diethylphenyl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(2'-trifluoromethylbiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
 1-{2-(3'-trifluoromethylbiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine; and
 1-{2-(4'-trifluoromethylbiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
as well as their salts and solvates or a pharmaceutically acceptable salt thereof.

Claim 11. (Currently amended): ~~Process~~ A process for the preparation of the compounds of formula (I') a compound according to Claim 8, ~~their salts or solvates and their or a salt or quaternary ammonium salts, characterized in that salt thereof wherein~~

- (a) an aryl-1,2,3,6-tetrahydropyridine of formula (II)



~~in which R'1 is as defined for the compounds (I') in Claim 8, is reacted with a compound of formula (III)~~




in which R'1, R'2 and R'3 are as defined for the compounds (I') in Claim 8 and L is a leaving group; and

(b) the compound of formula (I') thus obtained is isolated and optionally converted into one of its salts or ~~solvates or one of~~ its quaternary ammonium salts.

Claim 12. (Currently amended): Pharmaceutical A pharmaceutical composition containing as active ingredient a compound according to one of the Claims 8 to 10 Claim 8 together with a pharmaceutically acceptable vehicle or diluent.

Claim 13. (Currently amended): Pharmaceutical A pharmaceutical composition containing as active ingredient a compound of formula (I) such as defined in Claim 1 and a compound indicated in the symptomatic treatment of DAT, selected from the acetylcholinesterase inhibitors, the M1 muscarinic agonists, the nicotinic agonists, the NMDA receptor antagonists and the nootropic agents, and their pharmaceutically acceptable salts in combination with a compound of the formula



in which

R1 is halogen, a CF₃, (C₁-C₄) alkyl or (C₁-C₄) alkoxy group;

n is 0 or 1

R2 is hydrogen or a (C₁-C₄) alkyl group;

R3 is hydrogen, (C₁-C₆) alkyl, (C₁-C₆) alkoxy; halogen, a CF₃ group, hydroxy, a group selected from (C₃-C₇) cycloalkyl, phenyl, phenoxy, phenylmethyl or phenylethyl, said group being optionally mono- or polysubstituted on the phenyl group by halogen, CF₃, (C₁-C₄) alkyl or (C₁-C₄) alkoxy;

R4 and R5 is each independently hydrogen, (C₁-C₆) alkyl, (C₁-C₆) alkoxy, halogen, a CF₃ group or hydroxy;

or a salt, solvate or quaternary ammonium salt thereof.

Claim 14. (New) A pharmaceutical composition containing a compound according to claim 9 together with a pharmaceutically acceptable vehicle or diluent.

Claim 15. (New) A pharmaceutical composition containing a compound according to claim 10 together with a pharmaceutically acceptable vehicle or diluent.

Claim 16. (New) A method for the treatment and/or prophylaxis of diseases which involve neuronal degeneration which comprises administering to a patient in need of such treatment an effective amount of a composition according to claim 13.

Claim 17. (New) A compound according to Claim 8 wherein R'2 is phenyl, phenoxy, phenylmethyl or phenylethyl, said groups optionally substituted on the phenyl group by halogen, CF₃, (C₁-C₄)alkyl or (C₁-C₄)alkoxyl.

Claim 18. (New) A compound according to Claim 17 selected from the group consisting of
1-{2-(3'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
1-{2-(2'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
1-{2-(4'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
1-{2-(4-benzylphenyl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
1-{2-(4'-fluorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
1-{2-(biphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
1-{2-(2'-trifluoromethylbiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
1-{2-(3'-trifluoromethylbiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine; and
1-{2-(4'-trifluoromethylbiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine;
or a salt or solvate pharmaceutically acceptable salt thereof.